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Altered skeletal muscle lipid metabolism is a hallmark
feature of type 2 diabetes (T2D). We investigated muscle
lipid turnover in T2D versus BMI-matched control sub-
jects (controls) and examined whether putative in vivo
differences would be preserved in the myotubes. Male
obese T2D individuals (n = 6) and BMI-matched controls
(n = 6) underwent a hyperinsulinemic-euglycemic clamp,
VO2max test, dual-energy X-ray absorptiometry scan,
underwater weighing, and muscle biopsy of the vastus
lateralis. 14C-palmitate and 14C-oleate oxidation rates
and incorporation into lipids were measured in muscle
tissue as well as in primary myotubes. Palmitate oxida-
tion (controls: 0.99 6 0.17 nmol/mg protein; T2D: 0.53 6
0.07 nmol/mg protein; P = 0.03) and incorporation of
fatty acids (FAs) into triacylglycerol (TAG) (controls:
0.45 6 0.13 nmol/mg protein; T2D: 0.11 6 0.02 nmol/mg
protein; P = 0.047) were significantly reduced in muscle
homogenates of T2D. These reductions were not
retained for palmitate oxidation in primary myotubes
(P = 0.38); however, incorporation of FAs into TAG was
lower in T2D (P = 0.03 for oleate and P = 0.11 for palmi-
tate), with a strong correlation of TAG incorporation be-
tween muscle tissue and primary myotubes (r = 0.848,
P = 0.008). The data indicate that the ability to incorpo-
rate FAs into TAG is an intrinsic feature of human mus-
cle cells that is reduced in individuals with T2D.
Perturbations in lipid metabolism are associated with
insulin resistance and type 2 diabetes (T2D) (1). An in-
creased lipid supply, altered lipid partitioning, and re-
duced capacity for skeletal muscle fat oxidation have
been proposed to contribute to intramyocellular lipid
(IMCL) accumulation, lipotoxicity, and insulin resistance
(2–4). However, whether these characteristics of T2D are
inherited or simply the consequence of an altered lifestyle
and obesity remains an ongoing debate. In that context,
studies in human primary myotubes are of interest be-
cause cell autonomous models are devoid of direct envi-
ronmental influences. Hulver et al. (5) used such a model
to demonstrate that myotubes of nondiabetic, severely
obese individuals retain abnormal lipid partitioning (i.e.,
elevated triacylglycerol [TAG]-to-blunted fatty acid [FA]
oxidation ratio) (5). Of note, Aguer et al. (6) showed
that T2D subjects had increased IMCL content in muscle
tissue and that this elevation was maintained in primary
myotubes from these subjects compared with obese non-
diabetic control subjects, indicating that increased IMCL
content is preserved in vitro. However, the underlying
reason for this finding was not examined. Elevated FA
uptake could contribute to an increased IMCL content
observed in obesity and T2D. Some studies showed no
difference in uptake of FAs (7,8), whereas others showed
increased FA uptake in skeletal muscle of obese and T2D
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individuals (9). Likewise, studies in primary human myo-
tubes showed inconsistent results (6,10,11). Taken to-
gether, whether disturbances that exist in skeletal muscle
tissue lipid metabolism of T2D individuals are preserved in
the myotubes is unclear. If these disturbances persist in the
myotubes, are they related to any aspects of the in vivo
metabolic phenotype of the donors?
Because aberrant lipid metabolism is a central feature
of obesity and T2D, the goal of the current study was to
investigate whether disturbances exist in intramyocellular
FA metabolism in skeletal muscle of obese T2D individ-
uals compared with BMI- and age-matched normoglyce-
mic control subjects and to examine whether disturbances
in lipid metabolism are retained in vitro in the myotubes
established from these donors. This study is a unique
combination of ex vivo and in vitro analyses of lipid
metabolism in human skeletal muscle coupled with detailed
in vivo clinical phenotyping to assess insulin sensitivity
and aerobic capacity. We measured ex vivo FA metabo-
lism in skeletal muscle tissue and established primary
myotubes from these donors for in vitro studies. For
comparison, we measured FA metabolism in skeletal
muscle tissue of young, lean males. The myotubes were
used to investigate lipid turnover (FA uptake, oxidation,
and storage) using two different long-chain FAs. We
show that FA incorporation into TAG is impaired in T2D
muscle and in the myotubes established from T2D donors,
indicating that this perturbation is inherent in the T2D
muscle cell.
RESEARCH DESIGN AND METHODS
Participants
Twelve obese males with T2D (n = 6) and BMI- and age-
matched males (controls) participated. Participants with
T2D were given a diagnosis at least 1 year before the
study, were noninsulin dependent, had well-controlled di-
abetes (HbA1c , 7.8%; 62 mmol/mol; 177 mg/dL), and
had no diabetes-related comorbidities. Medication use
(metformin only or metformin plus sulfonylureas) was
stable for at least 6 months. Controls had no family his-
tory of diabetes. We included data from 16 young, lean
males who participated in another (unpublished) study.
The studies were approved by the Medical Ethical Com-
mittee of Maastricht University. All participants gave
written informed consent, performed a maximal aerobic
capacity test (VO2max) (12), and underwent dual-energy
X-ray absorptiometry or hydrostatic weighing for body
composition (13).
Hyperinsulinemic-Euglycemic Clamp
To measure peripheral insulin sensitivity, a two-step
hyperinsulinemic-euglycemic clamp was performed accord-
ing to DeFronzo et al. (14). Briefly, after an overnight fast,
a blood sample was drawn to measure glucose, insulin,
and free FA levels. Step 1 was initiated with an insulin
infusion at 10 mU/m2/min for 4 h with variable coinfu-
sion of 20% glucose. Step 2 consisted of a 2-h insulin
infusion at 40 mU/m2/min (20% variable glucose). The
M-value was calculated as the glucose infusion rate and
corrected for fat-free mass (FFM).
Muscle Biopsy
Muscle biopsy specimens were taken from the vastus
lateralis according to Bergstrom (15) and processed the
same day for ex vivo assays and cell culture. Remaining
tissue was stored at 280°C for future analyses.
Primary Muscle Cell Cultures
Primary skeletal muscle cell cultures were established as
previously described (16). Briefly, satellite cells were iso-
lated and grown in media supplemented with 16% FBS at
37°C and 5% CO2.
Real-Time Quantitative RT-PCR
Total RNA was isolated from ;20 mg of muscle tissue as
previously described (17). Primers and probes are shown
in Supplementary Table 1. Real-time quantitative RT-PCR
was performed as one-step reactions (18) as previously
described (19). All expression data were normalized by
dividing the target gene by the internal control gene.
Western Blots
Western blots were performed using antibodies directed
against PLIN2 and PLIN5 (Progen, Heidelberg, Germany),
PLIN3 (Santa Cruz Biotechnology, Heidelberg, Germany),
ATGL (Cell Signaling Technology, Danvers, MA), and sr-
actin (Sigma-Aldrich, St. Louis, MO). We were unable to
detect PLIN2 in myotubes. Secondary antibodies con-
tained a fluorescent tag (IRDye; LI-COR, Lincoln, NE).
Protein quantification was performed on an Odyssey
Infrared Imaging system (LI-COR).
Oil Red O Staining
Fresh muscle cryosections were stained for IMCL by Oil
Red O as described previously (20) and expressed per cell
surface area.
14C-Labeled Ex Vivo Palmitate Oxidation and Lipid
Incorporation
Palmitate oxidation was determined by measuring pro-
duction of 14CO2 and acid-soluble metabolites (
14C-ASMs)
in skeletal muscle homogenates containing 250 mmol/L
sucrose, 10 mmol/L Tris-HCl, 1 mmol/L EDTA, and
2 mmol/L ATP. Reactions were initiated with 0.2 mmol/L
palmitate and 0.0175 mmol/L [1-14C]-palmitate and termi-
nated with 70% perchloric acid. CO2 was trapped in 1N
NaOH (21,22). All in vitro experiments described next were
performed in triplicate per participant and normalized to
protein content.
In Vitro 14C-Palmitate Oxidation and Lipid
Incorporation
Palmitate oxidation was measured as production of 14CO2
and 14C-ASMs from [1-14C]-palmitate (1 mCi/mL), non-
labeled palmitate (100 mmol/L), and 1 mmol/L carnitine
after 3 h. Lipids were extracted from the myotubes, and
lipid incorporation was measured by thin-layer chroma-
tography. Bands corresponding to TAG and diacylglycerol
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(DAG) were quantified by liquid scintillation as previously
described (16).
In Vitro Pulse-Chase 14C-Oleate Experiments
Pulse-chase experiments were adapted from Koves et al.
(23). Muscle cells were grown and differentiated in 24-
well plates. a-Minimum essential medium supplemented
with 500 mmol/L oleate (2 mCi/mL [1-14C]-oleic acid)
complexed to BSA (1.25%) was added for 24 h on day 6
of differentiation (pulse). Cell samples were collected after
the 24-h pulse, lipids extracted, and lipid species sepa-
rated using thin-layer chromatography (16). These sam-
ples represent lipid synthesis capacity. The chase media
were supplemented with 1 mmol/L carnitine and collected
after 3 h to measure oxidation (14CO2 and
14C-ASMs) of
the endogenously labeled lipids.
In Vitro FA Uptake
FA uptake was measured by incubating myotubes with
FBS-free Dulbecco’s modified Eagle’s medium containing
0.2 mCi/mL [1-14C]-palmitate and 20 mmol/L nonlabeled
palmitate. Cells were incubated at 37°C for 4 min and
lysed in 0.1 mol/L NaOH. Lysates were counted by liquid
scintillation.
In Vitro TAG Levels
Intracellular TAG levels in differentiated myotubes were
measured using the method of Schwartz and Wolins (24).
Acyl-CoA:DAG Acyltransferase Activity Assay
Determination of acyl-CoA:DAG acyltransferase (DGAT)
activity was performed in cellular homogenates of the
human myotubes as previously described (25). DGAT1
inhibitor was provided by Dr. Robert V. Farese Jr. (26).
Data are presented as the rate of formation of 14C-TAG.
Statistics
Results are presented as mean6 SEM. Statistical analyses
were performed using SPSS version 16.0 for MacOS 16.0
(IBM Corp., Chicago, IL). Statistical comparisons between
conditions were performed using unpaired t tests. In the
case of in vitro lipid incorporation and corresponding pro-
tein expressions, a one-sided unpaired t test was performed
because a reduced incorporation in T2D myotubes was not
plausible based on the ex vivo data of lipid incorporation.
Pearson correlation coefficients were used to describe the




Clinical Characteristics of Individuals With T2D; Obese
Controls; and Young, Lean Subjects
Clinical characteristics are presented in Table 1. By defini-
tion, fasting plasma glucose levels were significantly higher
in individuals with T2D than in obese controls (controls:
5.22 6 0.15 mmol/L; T2D: 7.13 6 0.39 mmol/L). Fasting
circulating FAs were not different between groups (P =
0.76). Skeletal muscle insulin sensitivity (M-value at
40 mU/m2/min insulin) was lower, albeit not significantly,
in T2D than in obese controls (controls: 32.86 4.9 mmol/kg
FFM/min; T2D: 20.5 6 3.0 mmol/kg FFM/min; P = 0.05).
Aerobic capacity (VO2max) was significantly lower in
individuals with T2D than in controls (controls: 31.5 6
0.8 mL/min/kg FFM; T2D: 25.5 6 1.8 mL/min/kg FFM;
P , 0.05). As expected, clinical characteristics of young,
lean subjects were significantly different from obese con-
trols and individuals with T2D.
Ex Vivo
Intramuscular Lipid Content, Fiber Type, and FA
Metabolism
Intramuscular lipid content (IMCL) was similar between
obese controls and individuals with T2D (Fig. 1). We then
investigated FA oxidation rates in skeletal muscle homog-
enates using an exogenously supplied long-chain FA
(14C-palmitate). Palmitate oxidation to 14CO2 (com-
plete oxidation) was significantly reduced in individuals
with T2D (controls: 0.099 6 0.017 nmol/mg protein; T2D:
0.053 6 0.007 nmol/mg protein; P = 0.03) (Fig. 2A).
ASMs (incomplete oxidation) were not different between
the two groups (P = 0.86) (Fig. 2B). Thus, the ratio of
complete-to-incomplete oxidation (CO2:ASMs), which
indicates a more efficient FA metabolism, was also re-
duced in the T2D group (controls: 0.12 6 0.01; T2D:
0.07 6 0.01; P , 0.01) (Fig. 2C). The palmitate CO2:
Table 1—Clinical characteristics
Control (n = 6) T2D (n = 6) Young, lean (n = 16)
Age (years) 54.7 6 4.1A 58.3 6 2.1A 23.8 6 1.5B
BMI (kg/m2) 31.2 6 0.3A 30.8 6 0.3A 21.4 6 0.4B
% fat 32.8 6 3.0A 33.0 6 2.0A 14.3 6 1.2B
VO2max (mL/min/kg FFM) 31.5 6 0.8
A 25.5 6 1.8C 51.7 6 1.9B
Glucose (mmol/L) 5.22 6 0.15B 7.13 6 0.39A 5.15 6 0.14B
FAs (mmol/L) 0.78 6 0.39 0.62 6 0.17 —
M-value (mmol/kg FFM/min)* 32.8 6 4.9A 20.5 6 3.0A 73.6 6 4.1B
Data are mean6 SEM. FAs were not measured in the young, lean cohort. A,B,CSignificant differences between groups, P, 0.05 (one-way
ANOVA). *M-value, skeletal muscle insulin sensitivity at an insulin infusion rate of 40 mU/m2/min.
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ASMs correlated positively with VO2max (r = 0.537, P =
0.072) and inversely with fasting plasma glucose levels
(r = 20.566, P = 0.055) (Supplementary Fig. 1). The
same measurements performed in skeletal muscle tissue
from young, lean subjects revealed significantly higher
complete oxidation compared with both groups (Fig.
2A–C).
We next measured the incorporation of 14C-palmitate
into lipids in skeletal muscle homogenates. Although in-
corporation of 14C-palmitate into the total lipid pool was
similar between the two groups (Fig. 2D), we observed
decreased incorporation of 14C-palmitate into TAGs in
individuals with T2D (controls: 0.045 6 0.013 nmol/mg
protein; T2D: 0.011 6 0.002 nmol/mg protein; P = 0.047)
(Fig. 2E), with similar incorporation into DAGs (Fig. 2F).
This finding may indicate a blunted ability of the skeletal
muscle of individuals with T2D to efficiently store and
retain the lipids in the TAG pool.
Lean subjects showed significantly higher incorpora-
tion of palmitate into total lipids and a trend for higher
TAG incorporation compared with T2D (Fig. 2D–E). We
then measured the expressions of the lipid droplet coat
proteins PLIN5, PLIN3, and PLIN2 as well as the lipolytic
protein ATGL in individuals with T2D and obese controls.
PLIN5 was elevated in the T2D group (controls: 4.42 6
1.07 arbitrary units [au]; T2D: 9.38 6 2.14 au; P =
0.065) (Fig. 6A). Of note, PLIN5 protein was inversely
associated with ex vivo (tissue) palmitate oxidation
(CO2:ASMs vs. PLIN5: r = 0.69, P = 0.0122) (data not
shown). No significant differences were observed between
the two groups for PLIN3 (P = 0.185), PLIN2 (P = 0.145),
and ATGL (P = 0.775) expressions (Fig. 6B–D).
In Vitro
Exogenous FA Metabolism
In contrast to 14C-palmitate oxidation in muscle homoge-
nates, in vitro 14C-palmitate oxidation to CO2 was not
significantly lower in individuals with T2D (P = 0.38)
(Fig. 3A). Furthermore, oxidation to ASMs was not signif-
icantly different (P = 0.59) (Fig. 3B) and, consequently,
neither was CO2:ASMs (P = 0.38) (Fig. 3C). Moreover, in
vitro 14C-palmitate oxidation to CO2 did not correlate
with the ex vivo 14C-palmitate oxidation (P = 0.721)
(data not shown), suggesting that the capacity to oxidize
palmitate to CO2 is not an intrinsic property of the myo-
tubes established from these obese T2D and nondiabetic
individuals.
14C-palmitate incorporation into the total lipid pool
was lower in myotubes established from individuals
with T2D (controls: 5.84 6 1.46 nmol/mg protein; T2D:
3.28 6 0.27 nmol/mg protein; P = 0.058) (Fig. 3D). Sim-
ilarly, 14C-palmitate incorporation into TAG was reduced
in T2D myotubes (P = 0.085) (Fig. 3E); however, DAGs
were not significantly lower in individuals with T2D (P =
0.145) (Fig. 3F). In vitro 14C-palmitate incorporation into
TAG strongly correlated with ex vivo 14C-palmitate incor-
poration into TAG (r = 0.848, P = 0.008) (data not
shown). We next determined 14C-palmitate uptake and
DGAT activity in primary myotubes to investigate
whether a reduced FA uptake and/or reduced enzymatic
activity might underlie the reduced incorporation of FAs
into TAG. Palmitate uptake (P = 0.85) (Fig. 3G) and DGAT
activity did not significantly differ between groups (con-
trols: 9.28 6 0.92 nmol/h/mg protein; T2D: 7.69 6 1.17
nmol/h/mg protein; P = 0.31) (Fig. 3H).
Endogenous FA Metabolism
It has been suggested that endogenous rather than
exogenous IMCL oxidation is reduced in myotubes from
obese or obese T2D subjects compared with lean subjects
(27). Therefore, we examined 14C-oleate oxidation after
a 24-h pulse with 500 mmol/L oleate (in the absence of
carnitine to label the endogenous lipid pool). Oleate was
chosen instead of palmitate because of the lipotoxic
effects of palmitate on myotubes (28,29). Confirming
the lower 14C-palmitate incorporation into TAG, incorpo-
ration of 14C-oleate into the total lipid pool after 24 h was
significantly lower (1.7-fold) in myotubes from individuals
with T2D (controls: 16.3 6 2.40 nmol/mg protein; T2D:
9.5 6 0.78 nmol/mg protein; P = 0.02) (Fig. 4A). Further-
more, 14C-oleate incorporation into TAG was significantly
lower in myotubes from individuals with T2D (controls:
2.24 6 0.47 nmol/mg protein; T2D: 0.94 6 0.25 nmol/mg
protein; P = 0.03) (Fig. 4B). 14C-oleate incorporation into
DAG was not significantly different between the two
groups (P = 0.31) (Fig. 4C).
Following a 24-h incubation with 14C-oleate, oxidation
was initiated by the addition of carnitine and measured
after 3 h. Despite a reduced 14C-oleate incorporation into
TAG in myotubes from individuals with T2D, the oxidation
of endogenous 14C-oleate to CO2 was not significantly dif-
ferent between the groups (P = 0.384) (Fig. 4D). Likewise,
oxidation to ASMs was similar between the two groups
(controls: 0.070 6 0.012 nmol/mg protein; T2D: 0.058 6
0.015 nmol/mg protein; P = 0.543) (Fig. 4E). Consequently,
no differences were observed in CO2:ASMs (P = 0.49)
(Fig. 4F). Thus, in concert with the oxidation rates of
exogenous 14C-palmitate, oxidation of the endogenously
Figure 1—Intramyocellular neutral lipid content measured by Oil
Red O staining in combination with an immunofluorescence stain-
ing against slow myosin heavy chain to determine fiber type. Data
are mean 6 SEM. C, controls.
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labeled 14C-oleate pool was similar in primary myotubes
from both groups.
Of interest, in vivo basal glucose concentration was in-
versely related to in vitro incorporation of the endogenously
labeled lipid (14C-oleate) into the total lipid pool (r =20.615,
P = 0.033) (Fig. 5A) as well as TAG (r = 20.580, P = 0.048)
(Fig. 5B). Insulin sensitivity was also positively associated
with 14C-oleate incorporation in the total lipid pool (r =
0.602, P = 0.038) (Fig. 5C). It is important to note that there
was no difference in the basal myocellular lipid content be-
tween the two donor groups and, thus, no label dilution effect
on the metabolic assays was observed (data not shown).
Finally, we measured the expressions of the lipid
droplet coat proteins PLIN5 and PLIN3 as well as the
lipolytic protein ATGL before and after 24 h of a 400
mmol/L oleate load (Fig. 6E–G). We were unable to detect
PLIN2 protein in the myotubes. In contrast to the ex vivo
findings, PLIN5 was not different between the groups in
the basal condition. However, PLIN5 increased with the
FA load in the control group only (controls: P = 0.073;
T2D: P = 0.468) (Fig. 6E). PLIN3 and ATGL protein
expressions were not different between groups in the
basal condition or significantly changed in response to
the oleate load (Fig. 6F–G). Of note, PLIN5 protein
Figure 2—Ex vivo 14C-palmitate metabolism. A: 14C-palmitate oxidation to CO2. B:
14C-palmitate oxidation to ASMs. C: CO2:ASMs.
D: 14C-palmitate incorporation into total neutral lipids. E: 14C-palmitate incorporation into TAG. F: 14C-palmitate incorporation into DAG.
*P < 0.05 vs. control, **P < 0.01 vs. control, #P < 0.05 vs. T2D, ##P < 0.01 vs. T2D. Error bars represent SEM. C, control; L, young, lean.
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(postoleate load) was significantly associated with the
M-value at 40 mU of insulin (r = 0.61, P = 0.035) (data
not shown). We further examined whether differences
between groups were present in the mRNA expression
of genes involved in lipid metabolism (Supplementary Ta-
ble 2) in skeletal muscle tissue and/or primary myotubes.
Although no significant differences were observed, PGC1a
mRNA was significantly associated with increased palmi-
tate and oleate incorporation into TAG in the myotubes as
well as with DGAT activity, whereas PGC1a mRNA in the
muscle tissue was significantly associated with tissue
PLIN5 mRNA (Supplementary Table 3).
DISCUSSION
Obesity and T2D are associated with ectopic lipid
accumulation in tissues such as skeletal muscle (1,30–
33). IMCL content inversely correlates with peripheral
insulin sensitivity (34–37), suggesting that fat accumulation
Figure 3—In vitro exogenous 14C-palmitate metabolism. A: 14C-palmitate oxidation to CO2. B:
14C-palmitate oxidation to ASMs. C: CO2:
ASMs. D: 14C-palmitate incorporation into total neutral lipids. E: 14C-palmitate incorporation into TAG. F: 14C-palmitate incorporation into
DAG. G: 14C-palmitate uptake. H: DGAT activity. Error bars represent SEM. 2/2, basal condition; C, control; +D1i, with DGAT1 inhibitor.
1588 Skeletal Muscle Lipid Incorporation Diabetes Volume 63, May 2014
leads to insulin resistance. However, studies have shown
that lipid intermediates—not total IMCL per se—are
the true culprits of the development of insulin resistance
(38,39). Other studies have even suggested that increas-
ing the TAG storage capacity, specifically in skeletal mus-
cle, may be beneficial (40–42). Although these studies
used different methods (i.e., genetic manipulations, ex-
ercise), they clearly demonstrated a beneficial effect
of increased TAG storage on skeletal muscle insulin
sensitivity. In the current study, we investigated the
oxidative and storage capacities of both skeletal muscle
tissue and myotubes established from satellite cells of
obese individuals with T2D and BMI-matched nondia-
betic controls. We show that oxidation and incorpora-
tion of exogenously supplied long-chain FAs (palmitate)
into TAG is significantly blunted in muscle tissue from
individuals with T2D. Of importance, we demonstrate
that this blunted FA oxidative capacity is not retained
Figure 4—In vitro 14C-oleate pulse-chase metabolism. Primary myotubes were loaded with 400 mmol/L oleate for 24 h and then pulsed in
the presence of 1 mmol/L carnitine for 3 h. A–C: Incorporation of 14C-oleate was measured after 24-h incubation with 400 mmol/L oleate in
the absence of carnitine. A: Total lipid synthesis. B: TAG synthesis. C: DAG synthesis. Oxidation rates were measured during the 3-h pulse
period. D: 14C-oleate oxidation to CO2. E:
14C-oleate oxidation to ASMs. F: CO2:ASMs. *P < 0.05. Error bars represent SEM. C, controls;
OA, oleate in the absence of carnitine.
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in primary myotubes from these patients. However, myo-
tubes of individuals with T2D show reduced incorporation
of exogenous palmitate into TAG, and this is significantly
related to the impaired palmitate incorporation into TAG
observed ex vivo. Moreover, incorporation of oleate into
the total neutral lipid pool, specifically the TAG pool, after
prolonged FA incubation in the absence of carnitine sup-
plementation is significantly reduced in the myotubes from
individuals with T2D. Because the absence of carnitine
prevents FA oxidation, this measurement mainly reflects
Figure 5—Correlations between in vivo measures of glucose and insulin sensitivity and in vitro endogenous lipid incorporation. Primary
myotubes were loaded with 400 mmol/L oleate for 24 h and then pulsed in the presence of 1 mmol/L carnitine for 3 h. Incorporation of 14C-
oleate was measured after 24-h incubation with 400 mmol/L oleate in the absence of carnitine. Basal plasma glucose levels were inversely
related to total lipid synthesis (A) and TAG synthesis (B). Insulin sensitivity (M-value at a 40 mU/m2/min insulin infusion rate) was positively
associated with total lipid synthesis (C ).
Figure 6—Ex vivo and in vitro protein expressions. Lipid droplet coating proteins PLIN5 (A), PLIN3 (B), and PLIN2 (C ) as well as the lipolytic
protein ATGL (D) were measured in the muscle tissues of the control and T2D individuals. Primary myotubes were loaded with 400 mmol/L
oleate for 24 h and then harvested for protein. E–G: Protein expressions were measured before (Basal) and after the 24-h incubation with
400 mmol/L oleate in the absence of carnitine (OA). E: PLIN5. F: PLIN3. G: ATGL. Sr-actin was used as an internal control for all Western
blots. Error bars represent SEM. C, controls.
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unidirectional TAG synthesis. Therefore, we conclude that
lower lipid incorporation is an intrinsic metabolic charac-
teristic of skeletal muscle of obese individuals with T2D
compared with BMI-matched controls.
We show a blunted complete oxidation of palmitate in
the skeletal muscle tissue of obese individuals with T2D
compared with BMI-matched controls and young, lean
subjects. Because there were no differences in the ASMs,
the ratio of complete to incomplete oxidation was also
reduced in individuals with T2D. These findings extend
those of Hulver et al. (43), who demonstrated aberrant
exogenous FA oxidation in the skeletal muscle of obese
and severely obese (BMI 53.8 6 3.5 kg/m2) individuals
compared with lean control subjects. In this context, the
current data imply that T2D is associated with reduced
tissue FA oxidation independent of BMI. However, we did
not observe significant differences in oxidation of exoge-
nous palmitate to CO2 and ASMs between myotubes of
obese individuals with T2D and BMI-matched controls.
We then examined whether FA oxidation from endoge-
nous lipid pools was compromised in the myotubes of
these individuals with T2D. After an overnight loading
of the myotube lipid pool with oleate, no differences in
endogenous FA oxidation rates between obese and T2D
myotubes were observed. These findings contrast those of
Gaster (27), who demonstrated that complete oxidation
of endogenous, but not exogenous, FAs was reduced in
T2D myotubes compared with those from obese control
subjects. One major difference between the current study
and Gaster is that we included subjects who were margin-
ally obese (although all had a BMI .30 kg/m2), resulting
in a lower average BMI than that in Gaster. Another po-
tential explanation is that these two studies compared
distinct subgroups of the obese population that may
have been exposed to different environmental factors,
which could uniquely affect a varied genetic or epigenetic
background. The current data suggest that a reduced myo-
cellular fat oxidative capacity in individuals with T2D may
not be an intrinsic characteristic but, rather, a conse-
quence of environment.
One bout of exercise has been shown to improve the
capacity to store TAG in muscle and, thereby, prevent
lipid-induced insulin resistance (42). Moreover, by use of
in vivo infusion of 13C-palmitate, Bergman et al. (44)
showed that palmitate incorporation into skeletal muscle
TAG was increased in endurance athletes compared with
sedentary control subjects. In the current study, we found
that incorporation of palmitate into TAG but not into
DAG was blunted in skeletal muscle of individuals with
T2D compared with BMI-matched controls and young,
lean subjects. Collectively, these reports indicate that in-
creased channeling of FAs toward storage in the form of
TAG in skeletal muscle is associated with an improved
metabolic profile. In contrast to the reduced oxidative
capacity in the muscle tissue of individuals with T2D,
which was not retained in the myotubes, reduced incor-
poration of FAs into TAG was retained in the myotubes of
individuals with T2D. By reducing lipid intermediate ac-
cumulation, a high capacity to channel FAs toward intra-
myocellular neutral lipid (i.e., TAG) storage may protect
against lipid-induced insulin resistance. Thus, a reduced
rate of TAG storage in T2D may be an important factor in
the development of lipid-induced insulin resistance in
these individuals. In support of this hypothesis, an en-
hanced capacity of the myotubes to incorporate endog-
enously labeled oleate into the total lipid pool, and
specifically TAG, was associated with reduced basal glu-
cose concentration and insulin sensitivity.
The reason for the retained aberrant lipid incorpora-
tion capacity in T2D is so far unknown. We investigated
whether skeletal muscle FA uptake may underlie these
findings. Skeletal muscle FA uptake is a controversial
topic, with some investigators finding no difference in
uptake of FAs (7,8) and others showing increased FA
uptake in skeletal muscle of obese and T2D individuals
(9). In the current study, we could not detect differences
in short-term FA uptake rates in cultured myotubes of
individuals with T2D compared with BMI-matched con-
trols. Reduced TAG incorporation in the setting of unal-
tered FA uptake, oxidation, or DAG incorporation might
indicate that the FAs are incorporated into other lipid
species not measured here that may (i.e., ceramides)
(45) or may not yet be associated with insulin resistance
and T2D. In addition, we could not detect differences in
mRNA levels of lipid metabolism genes or in enzymatic
activity of DGAT between T2D and obese controls. How-
ever, we did observe significantly positive associations of
PGC1a mRNA with DGAT activity and the capacity to
incorporate both palmitate and oleate into TAG in the
myotubes. These relationships support our previous find-
ings that highlight the role of PGC1a in the regulation of
intramuscular lipid droplet programming in mice and
humans (23). Finally, we focused on expression levels of
the lipid droplet coat proteins PLIN5, PLIN3, and PLIN2
as well as the lipolytic protein ATGL in both muscle tissue
and myotubes because we have previously shown in ani-
mal studies that overexpressing PLIN2 or PLIN5 increases
TAG storage capacity and results in the prevention of
high-fat–induced insulin resistance (40,46). In the current
study, we found that PLIN5 was elevated in the muscle
tissue of the T2D individuals but not in their myotubes.
This finding is surprising given that the tissue lipid levels
were not different between the two groups and that
PLIN5 has been associated with insulin sensitivity in
humans (38). However, PLIN5 protein expression was
not different between the two groups of myotubes in
the basal state, which is in line with the similar lipid levels
observed in these myotubes. Moreover, PLIN5 protein
levels increased after an overnight oleate load in the
BMI-matched myotubes but not in myotubes derived
from T2D individuals. These data are consistent with
the increased neutral lipid and TAG storage observed in
myotubes from the BMI-matched controls. In support of
the notion that an increased TAG storage capacity is
diabetes.diabetesjournals.org Sparks and Associates 1591
protective against the development of insulin resistance
in conditions of increased lipid supply, we demonstrate
that PLIN5 protein levels (postoleate load) in myotubes
were positively related to insulin sensitivity. In the con-
text of similar lipid levels in the tissue and cells, it is not
surprising that the expressions of PLIN2 and PLIN3 were
not different between the two groups. However, when
taken together, future studies should investigate the in-
trinsic pathways in muscle lipid turnover (and its associ-
ated proteins) to identify the critical regulation sites.
In summary, the data show that skeletal muscle tissue
lipid oxidation and FA incorporation into TAG are
perturbed in obese individuals with T2D compared with
BMI-matched controls but that only the disturbances in
TAG incorporation are conserved in cultured myotubes
from these individuals. The results are consistent with the
view that lipid turnover has a significant impact on
insulin sensitivity and glucose homeostasis. Future stud-
ies using primary human muscle cell models with muscle-
specific modulations of the lipid turnover pathways may
help to unravel the specific regulation sites of skeletal
muscle and whole-body energy metabolism in vivo. These
findings could have profound implications for how we use
precision medicine to treat, manage, and prevent T2D in
the future.
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